<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496921</url>
  </required_header>
  <id_info>
    <org_study_id>VITK-FK</org_study_id>
    <nct_id>NCT04496921</nct_id>
  </id_info>
  <brief_title>Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis</brief_title>
  <acronym>VITK-FK</acronym>
  <official_title>Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis : A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF) patients are at risk for vitamin K deficiencies. Supplementation for&#xD;
      fat-soluble vitamins A, D, and E is well established, but in CF, there is little data for&#xD;
      vitamin K concerning the optimal dose and frequency of supplementation. Beyond its known role&#xD;
      in coagulation, research has highlighted the role of vitamin K for bone health and the&#xD;
      control of blood sugar levels. However, after pulmonary complications, the risk of diabetes&#xD;
      and bone diseases are two important and frequent complications of CF. Patients with CF being&#xD;
      at risk of vitamin K deficiencies, this vitamin could play a role in these complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a pilot study (carried out to assess its feasibility on a larger&#xD;
      scale) to evaluate if a supplement of vitamin K improves vitamin K serum levels in CF&#xD;
      patients by comparing:&#xD;
&#xD;
        -  Group A: a vitamin K supplement of 2mg, every day for 6 months&#xD;
&#xD;
        -  Group B: a vitamin K supplement of 7mg, twice a week for 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Clinical care of patients with CF changed following COVID-19 pandemic (OGTT not performed at&#xD;
    the CF clinic since March 2020); in consequence, this study is no longer feasible.&#xD;
  </why_stopped>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: vitamin K supplement of 2 mg, once a day for 6 months&#xD;
Group B: vitamin K supplement of 7 mg, twice a week for 6 months</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum vitamin K levels from baseline at 6 months</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Impact of supplementation on vitamin K serum levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in osteocalcin levels from baseline at 6 months</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Impact of supplementation on osteocalcin levels (Total and uncarboxylated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's perception and side effects of the supplement</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marker levels</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Impact of supplementation on bone marker C-Telopeptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic marker levels</measure>
    <time_frame>0, 3 and 6 months</time_frame>
    <description>Impact of supplementation on HbA1c levels and fructosamine levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Vitamin K supplement, dose #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin K supplementation with dose #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K supplement, dose #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin K supplementation with dose #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K supplementation, dose #1</intervention_name>
    <description>Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.</description>
    <arm_group_label>Vitamin K supplement, dose #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K supplementation, dose #2</intervention_name>
    <description>Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.</description>
    <arm_group_label>Vitamin K supplement, dose #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with CF&#xD;
&#xD;
          -  Aged above 18 years&#xD;
&#xD;
          -  Pancreatic insufficient&#xD;
&#xD;
          -  Subjects with an OGTT test in the last 12 months or subjects who are diabetic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receive or have received, in the last 6 months, a supplement of vitamin K (dose&#xD;
             greater than 500 mcg per day)&#xD;
&#xD;
          -  Subjects with a pulmonary function under 30%&#xD;
&#xD;
          -  Subjects with severe gastrointestinal disease (Crohn disease, coeliac disease and&#xD;
             recent (&lt;1 year) history of intestinal occlusion).&#xD;
&#xD;
          -  Subjects with a history of liver disease (severe or transplant)&#xD;
&#xD;
          -  Known allergy or intolerance to phylloquinone (oral form of vitamin K)&#xD;
&#xD;
          -  Pregnancy (current or planned in the next 6 months)&#xD;
&#xD;
          -  Subjects with signs of active secondary infections should wait at least 1 month after&#xD;
             the end of antibiotic treatment in order to be included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémi Rabasa-Lhoret, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Clinical Research Institute (IRCM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Supplementation</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

